A股異動 | 南大光電(300346.SZ)漲超13% ArF光刻膠產品通過客户認證
格隆匯12月18日丨南大光電(300346.SZ)現報37.56元,漲13.06%,暫成交7.6億元,最新總市值152億元。南大光電昨日晚間公佈,公司控股子公司寧波南大光電自主研發的ArF光刻膠產品近日成功通過客户的使用認證。“ArF光刻膠產品開發和產業化”是寧波南大光電承接國家“02專項”的一個重點攻關項目。此次產品的認證通過,標誌着“ArF光刻膠產品開發和產業化”項目取得了關鍵性的突破,成為國內通過產品驗證的第一隻國產ArF光刻膠,為全面完成項目目標奠定了堅實的基礎。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.